<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id><journal-id journal-id-type="iso-abbrev">Arq. Bras. Cardiol</journal-id><journal-title-group><journal-title>Arquivos Brasileiros de Cardiologia</journal-title></journal-title-group><issn pub-type="ppub">0066-782X</issn><issn pub-type="epub">1678-4170</issn><publisher><publisher-name>Sociedade Brasileira de Cardiologia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25119894</article-id><article-id pub-id-type="pmc">4206361</article-id><article-id pub-id-type="doi">10.5935/abc.20140109</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Ivabradine Improves Heart Rate Variability in Patients with Nonischemic
Dilated Cardiomyopathy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kurtoglu</surname><given-names>Ertugrul</given-names></name><xref ref-type="aff" rid="aff01">1</xref><xref ref-type="corresp" rid="c01"/></contrib><contrib contrib-type="author"><name><surname>Balta</surname><given-names>Sevket</given-names></name><xref ref-type="aff" rid="aff02">2</xref></contrib><contrib contrib-type="author"><name><surname>Karakus</surname><given-names>Yasin</given-names></name><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Yasar</surname><given-names>Erdogan</given-names></name><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Cuglan</surname><given-names>Bilal</given-names></name><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Kaplan</surname><given-names>Ozgur</given-names></name><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Gozubuyuk</surname><given-names>Gokhan</given-names></name><xref ref-type="aff" rid="aff01">1</xref></contrib></contrib-group><aff id="aff01"><label>1</label>Department of Cardiology, Malatya State Hospital, Malatya, Turkey</aff><aff id="aff02"><label>2</label>Department of Cardiology, Eskisehir Military Hospital, Eskisehir,
Turkey</aff><author-notes><corresp id="c01"><bold>Mailing Address: Ertugrul Kurtoglu,</bold> Malatya State Hospital, Ertugrul
Kurtoglu - Ankara Cad. Ozalper Mah., Malatya - Turkey. Email:
<email>erkurtoglu@hotmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><month>10</month><year>2014</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><month>10</month><year>2014</year></pub-date><volume>103</volume><issue>4</issue><fpage>308</fpage><lpage>314</lpage><history><date date-type="received"><day>22</day><month>1</month><year>2014</year></date><date date-type="rev-recd"><day>23</day><month>3</month><year>2014</year></date><date date-type="accepted"><day>24</day><month>3</month><year>2014</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Ivabradine is a novel specific heart rate (HR)-lowering agent that improves
event-free survival in patients with heart failure (HF).</p></sec><sec><title>Objectives</title><p>We aimed to evaluate the effect of ivabradine on time domain indices of heart rate
variability (HRV) in patients with HF.</p></sec><sec><title>Methods</title><p>Forty-eight patients with compensated HF of nonischemic origin were included.
Ivabradine treatment was initiated according to the latest HF guidelines. For HRV
analysis, 24-h Holter recording was obtained from each patient before and after 8
weeks of treatment with ivabradine.</p></sec><sec><title>Results</title><p>The mean RR interval, standard deviation of all normal to normal RR intervals
(SDNN), the standard deviation of 5-min mean RR intervals (SDANN), the mean of the
standard deviation of all normal-to-normal RR intervals for all 5-min segments
(SDNN index), the percentage of successive normal RR intervals exceeding 50 ms
(pNN50), and the square root of the mean of the squares of the differences between
successive normal to normal RR intervals (RMSSD) were low at baseline before
treatment with ivabradine. After 8 weeks of treatment with ivabradine, the mean HR
(83.6 &#x000b1; 8.0 and 64.6 &#x000b1; 5.8, p &#x0003c; 0.0001), mean RR interval (713
&#x000b1; 74 and 943 &#x000b1; 101 ms, p &#x0003c; 0.0001), SDNN (56.2 &#x000b1; 15.7 and
87.9 &#x000b1; 19.4 ms, p &#x0003c; 0.0001), SDANN (49.5 &#x000b1; 14.7 and 76.4 &#x000b1;
19.5 ms, p &#x0003c; 0.0001), SDNN index (24.7 &#x000b1; 8.8 and 38.3 &#x000b1; 13.1 ms,
p &#x0003c; 0.0001), pNN50 (2.4 &#x000b1; 1.6 and 3.2 &#x000b1; 2.2 %, p &#x0003c; 0.0001),
and RMSSD (13.5 &#x000b1; 4.6 and 17.8 &#x000b1; 5.4 ms, p &#x0003c; 0.0001)
substantially improved, which sustained during both when awake and while
asleep.</p></sec><sec><title>Conclusion</title><p>Our findings suggest that treatment with ivabradine improves HRV in nonischemic
patients with HF.</p></sec></abstract><kwd-group><kwd>Anti-Arrhythmia Agents / therapeutic use</kwd><kwd>Heart Rate</kwd><kwd>Cardiomyopathy, Dilated</kwd></kwd-group></article-meta></front><body><sec sec-type="introduction"><title>Introduction</title><p>Chronic heart failure (CHF) is a major public health problem and a substantial clinical,
social, and economic burden, requiring repeated hospitalization and causing a
substantial reduction in the quality of life of patients<sup><xref rid="r01" ref-type="bibr">1</xref></sup>. Despite the advances in medicine, prognosis remains poor
for patients with CHF, with a 7-year mortality rate of 75%<sup><xref rid="r02" ref-type="bibr">2</xref></sup>. For CHF with reduced left ventricular ejection fraction,
the latest heart failure guidelines have extended the treatment possibilities by
incorporating ivabradine, a novel specific heart rate-lowering agent that acts
specifically on the sino-atrial node by selectively inhibiting the inward "funny"
current (If) of cardiac pacemakers cells, thus preserving cardiac contractility, impulse
conduction, and blood pressure<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r03" ref-type="bibr">3</xref>-<xref rid="r05" ref-type="bibr">5</xref></sup>.
In a clinical trial, it was found that lowering the heart rate of CHF patients with the
help of ivabradine administration reduces morbidity and mortality<sup><xref rid="r06" ref-type="bibr">6</xref></sup>.</p><p>Heart rate variability (HRV) is a noninvasive, practical, and reproducible measure of
autonomic nervous system function. A heart rate that is variable and responsive to
demands is believed to bestow a survival advantage, whereas diminished HRV may be
associated with poor cardiovascular outcomes<sup><xref rid="r07" ref-type="bibr">7</xref>,<xref rid="r08" ref-type="bibr">8</xref></sup>. Available evidence
suggests that reduced HRV has prognostic significance for mortality in CHF
population<sup><xref rid="r09" ref-type="bibr">9</xref>-<xref rid="r11" ref-type="bibr">11</xref></sup>. Previous studies have found a 20% reduction in
mortality risk with each 10-ms increase in the standard deviation of all
normal-to-normal RR intervals (SDNN)<sup><xref rid="r12" ref-type="bibr">12</xref></sup>. Because autonomic imbalance resulting from sympathetic overactivity
and parasympathetic withdrawal is a characteristic feature of CHF, we hypothesized that
ivabradine may improve the vagal reflexes to the heart and reduce the sympathetic
overactivity in patients with nonischemic dilated cardiomyopathy (DCM)<sup><xref rid="r13" ref-type="bibr">13</xref></sup>. Therefore, the aim of this study was to
investigate the effects of ivabradine on heart rate variability (HRV) in patients with
nonischemic DCM. This patient population was chosen in an attempt to study HRV free of a
possible confounding effect of ivabradine on coronary ischemia<sup><xref rid="r14" ref-type="bibr">14</xref></sup>.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study population</title><p>Patients with CHF of nonischemic origin were included in the present study. The age
of the eligible patients ranged from 18 to 90 years. The patients had 1) a diagnosis
of CHF that lasted for at least 3 months before entering the study 2) clinically
stability in the 4 weeks before entering the study, which was defined by the absence
of clinically significant changes in the physical signs of heart failure, absence of
clinically significant changes in self-reported symptoms, and no changes in
prescribed medicines during the study period, 3) a left ventricular ejection fraction
of 0.35 or less as documented by echocardiography performed within the previous 3
months, 4) a sinus rhythm with a resting heart rate of &#x02265; 70 beats/ min (bpm)
as assessed from 12-lead electrocardiogram on 2 consecutive visits, 5) absence of
coronary artery disease as evaluated by coronary angiography performed within 1 year,
6) optimized and unchanged chronic heart failure medications and dosages in
accordance with contemporary guideline recommendations (&#x003b2;-blockers,
angiotensin-converting enzyme inhibitors [ACEI] and/or angiotensin II
receptor blockers [ARB], diuretics as necessary) for &#x02265; 8 weeks
before entering the study, and 7) the New York Heart Association (NYHA) functional
class II to III. The cause of the heart failure was idiopathic in all patients. This
patient population was specifically chosen because ivabradine shows antianginal and
anti-ischemic effects in patients with ischemic dilated cardiomyopathy, which could
have a confounding effect on HRV<sup><xref rid="r14" ref-type="bibr">14</xref></sup>.
The diagnosis of left ventricular (LV) systolic dysfunction was established according
to the recommendations of the American Society of Echocardiography<sup><xref rid="r15" ref-type="bibr">15</xref></sup>.</p><p>Exclusion criteria included acute decompensated heart failure, ischemic heart
disease, congenital heart disease, class 3 or higher chronic obstructive pulmonary
disease (COPD), heart rate &#x0003c;60 beats/min, sick sinus syndrome, second-degree and
third-degree atrioventricular block, active myocarditis, atrial fibrillation or
flutter, severe or uncontrolled hypertension (systolic blood pressure &#x0003e;180 mmHg or
diastolic blood pressure &#x0003e;110 mmHg), diabetes mellitus, autonomic neuropathy,
known severe liver disease or renal disease, and thyroid disorders.</p></sec><sec><title>Study protocol</title><p>Patients who fulfilled the inclusion criteria underwent 24-h Holter monitoring for
HRV analysis before ivabradine treatment was initiated. Ivabradine was administered
along with background cardiovascular therapy, which was optimized in accordance with
the contemporary guideline recommendations. After the 24-h Holter monitoring,
ivabradine treatment was started according to the current heart failure guidelines.
Titration of ivabradine was performed as reported elsewhere<sup><xref rid="r06" ref-type="bibr">6</xref></sup>. The starting dose of ivabradine was 5 mg twice daily.
After a 2-week titration period, the dose was increased to 7.5 mg twice daily unless
the resting heart rate was &#x02264;60 bpm. If the resting heart rate was &#x0003c; 50 bpm or the
patient experienced signs or symptoms related to bradycardia, the dose was reduced to
2.5 mg twice daily. If the heart rate was between 50 and 60 bpm, the dose was
maintained at 5 mg twice daily. Follow-up visits took place once every 2 weeks. At
each follow-up visit, clinician either maintained or increased the drug dose. The
24-h Holter monitoring was repeated during the 8<sup>th</sup> week of ivabradine
treatment. The study was approved by the local ethics committees and adhered to the
Declaration of Helsinki. Informed consent was obtained from all subjects before the
start of the study.</p></sec><sec><title>Holter analysis</title><p>All patients who fulfilled the inclusion criteria underwent a 24-h
electrocardiographic monitoring before ivabradine treatment and at 8 weeks while on
treatment with ivabradine. A six-channel digital Holter recorder (DMS 300-3A Digital
Holter Recorder, California, USA) with built-in flash memory that was scanned by a
computer was used for monitoring all patients. The patients were asked to continue
their normal activities and their normal sleep-wake rhythm during the ambulatory
electrocardiographic monitoring and were provided with a diary in which they were
asked to record the sleep timings. The tapes were analyzed by a cardiologist. The HRV
measurements were obtained using a commercially available Holter software program
(CardioScan 12.0, DMS, USA). After the computerized primary analysis, all recordings
were edited manually for eliminating from supraventricular, ventricular ectopy and
artifacts. Recordings lasting for at least 22 h and having sufficient quality for
evaluation were included in the analysis. When these criteria were not met, the
recordings were repeated. The time domain parameters were assessed from the Holter
recordings following the recommendations of the European Society of Cardiology and
the North American Society of Pacing Electrophysiology<sup><xref rid="r07" ref-type="bibr">7</xref></sup>. The following time domain indices of HRV were
measured: (1) The mean of all normal RR intervals in ms (RR, ms); (2) the standard
deviation of all normal to normal RR intervals (SDNN, ms); (3) the mean of the
standard deviation of all normal to normal RR intervals for all 5-min segments (SDNN
index, msec); (4) the standard deviation of 5-min mean RR intervals (SDANN, ms), (5)
the percentage of successive normal RR intervals exceeding 50 ms (pNN50, %), and (6)
the square root of the mean of the squares of the differences between successive
normal-to-normal RR intervals (RMSSD, ms).</p></sec><sec><title>Statistical analysis</title><p>Statistical analyses were performed using the SPSS software, version 17.0 (SPSS for
Windows 12.0, Chicago, Ill). All data were tested for normal distribution using the
Kolmogorov-Smirnov test. Continuous variables were presented as mean and standard
deviation, and categorical variables as frequency and percentage. Changes in the time
indices of HRV were tested by paired samples t-test for normally distributed data and
two related samples test (Wilcoxon Signed Rank test) for non-normally distributed
data. All p values were two-tailed and values less than 0.05 were considered to
indicate statistical significance.</p></sec></sec><sec sec-type="results"><title>Results</title><p>Initially, a total 60 patients were included in the study. Twelve patients were excluded
prematurely from the study because of visual side effects of ivabradine (2 patients),
excessive bradycardia (4 patients), and lost during follow-up (6 patients). Fourth-eight
patients completed the study and were included in the analysis. Baseline characteristics
of the study population and their HRV parameters are listed in <xref ref-type="table" rid="t01">Table 1</xref>. The average age was 70.9&#x000b1;10.6 years. There were 27
men and 21 women and all study participants were white. Mean left ventricular ejection
fraction was 23.0&#x000b1;5.4 %. The mean dosage of ivabradine was 5.8&#x000b1;1.6 mg
twice daily at 8 weeks. Acceptable Holter recordings were collected for 100% of the
population both at baseline and at 8 weeks. A total of 5 Holter recordings at baseline
and 4 Holter recordings after ivabradine treatment were made for enhanced quality.</p><table-wrap id="t01" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics of the study population</p></caption><table frame="hsides" rules="rows"><tbody><tr align="center"><td colspan="3" rowspan="1"><bold>Demographic parameters</bold></td></tr><tr><td colspan="2" rowspan="1">Age, years</td><td align="center" rowspan="1" colspan="1">70.9 &#x000b1; 10.6</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">Women, n (%)</td><td align="center" rowspan="1" colspan="1">21 (43)</td></tr><tr><td colspan="2" rowspan="1">BMI, kg/m<sup>2</sup></td><td align="center" rowspan="1" colspan="1">26.6 &#x000b1; 3.3</td></tr><tr><td colspan="2" rowspan="1">Duration of HF, years</td><td align="center" rowspan="1" colspan="1">6.3 &#x000b1; 1.8</td></tr><tr><td colspan="2" rowspan="1">Hypertension, n (%)</td><td align="center" rowspan="1" colspan="1">25 (52)</td></tr><tr><td colspan="2" rowspan="1">Cigarette smoking, n (%)</td><td align="center" rowspan="1" colspan="1">9 (19)</td></tr><tr><td colspan="2" rowspan="1">Previous stroke, n (%)</td><td align="center" rowspan="1" colspan="1">3 (6)</td></tr><tr align="center"><td colspan="3" rowspan="1"><bold>Cardiac parameters</bold></td></tr><tr><td colspan="2" rowspan="1">SBP, mmHg</td><td align="center" rowspan="1" colspan="1">110.5 &#x000b1; 9.4</td></tr><tr><td colspan="2" rowspan="1">DBP, mmHg</td><td align="center" rowspan="1" colspan="1">72.2 &#x000b1; 7.9</td></tr><tr><td colspan="2" rowspan="1">Left ventricular ejection fraction, %</td><td align="center" rowspan="1" colspan="1">23.0 &#x000b1; 5.4</td></tr><tr><td colspan="2" rowspan="1">eGFR, mL/min</td><td align="center" rowspan="1" colspan="1">75.3 &#x000b1; 10.9</td></tr><tr><td colspan="2" rowspan="1">NYHA class II, n (%)</td><td align="center" rowspan="1" colspan="1">20 (42)</td></tr><tr><td colspan="2" rowspan="1">NYHA class III, n (%)</td><td align="center" rowspan="1" colspan="1">28 (58)</td></tr><tr align="center"><td colspan="3" rowspan="1"><bold>Background medications, n (%)</bold></td></tr><tr><td colspan="2" rowspan="1">&#x000df;-blocker</td><td align="center" rowspan="1" colspan="1">46 (96)</td></tr><tr><td colspan="2" rowspan="1">Target dose of &#x000df;-blocker</td><td align="center" rowspan="1" colspan="1">25 (52)</td></tr><tr><td colspan="2" rowspan="1">ACE inhibitor and/or ARB</td><td align="center" rowspan="1" colspan="1">45 (94)</td></tr><tr><td colspan="2" rowspan="1">Diuretics (excluding antialdosterone)</td><td align="center" rowspan="1" colspan="1">44 (91)</td></tr><tr><td colspan="2" rowspan="1">Antialdosterone diuretics</td><td align="center" rowspan="1" colspan="1">26 (54)</td></tr><tr><td colspan="2" rowspan="1">Statin</td><td align="center" rowspan="1" colspan="1">8 (16)</td></tr><tr><td colspan="2" rowspan="1">Amiodarone</td><td align="center" rowspan="1" colspan="1">9 (19)</td></tr><tr><td colspan="2" rowspan="1">Cardiac glycosides</td><td align="center" rowspan="1" colspan="1">8 (16)</td></tr><tr><td colspan="3" rowspan="1">Devices</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">ICD</td><td align="center" rowspan="1" colspan="1">4 (8)</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">CRT</td><td align="center" rowspan="1" colspan="1">3 (6)</td></tr></tbody></table><table-wrap-foot><fn><p>ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blocker; BMI:
body mass index; CRT: cardiac resynchronization therapy; DBP: diastolic blood
pressure; eGFR: estimated glomerular filtration rate; HF: heart failure; ICD:
implantable cardioverter defibrillator; NYHA: New York Heart Association; SBP:
systolic blood pressure</p></fn></table-wrap-foot></table-wrap><p>In our cohort of idiopathic dilated heart failure patients with low ejection fractions,
the mean RR interval, SDNN, SDANN, SDNN index, pNN50, and RMSSD were markedly low at
baseline (<xref ref-type="table" rid="t01">Table 1</xref>). After 8 weeks of treatment
with ivabradine, the mean RR interval, SDNN, SDANN, and SDNN index increased
significantly (<xref ref-type="table" rid="t02">Table 2</xref>). Parameters of
parasympathetic activity, pNN50 and RMSSD, also increased after ivabradine
administration (<xref ref-type="table" rid="t02">Table 2</xref>). This significant
increase in time domain indices of HRV observed after ivabradine administration was
persisted both when the patient was awake and while asleep (<xref ref-type="table" rid="t03">Table 3</xref>).</p><table-wrap id="t02" orientation="portrait" position="float"><label>Table 2</label><caption><p>Changes in time domain HRV indices of the study population before and after
ivabradine treatment</p></caption><table frame="hsides" rules="rows"><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th rowspan="1" colspan="1">Before treatment</th><th rowspan="1" colspan="1">After treatment</th><th rowspan="1" colspan="1">Change. %</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">HR, bpm</td><td align="center" rowspan="1" colspan="1">83.6 &#x000b1; 6.0</td><td align="center" rowspan="1" colspan="1">64.6 &#x000b1; 5.8<xref ref-type="table-fn" rid="tfn01t02">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1">- 33.3</td></tr><tr><td rowspan="1" colspan="1">RR interval, ms</td><td align="center" rowspan="1" colspan="1">713 &#x000b1; 74</td><td align="center" rowspan="1" colspan="1">943 &#x000b1; 101<xref ref-type="table-fn" rid="tfn01t02">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1">+ 34.1</td></tr><tr><td rowspan="1" colspan="1">SDNN, ms</td><td align="center" rowspan="1" colspan="1">56.2 &#x000b1; 15.7</td><td align="center" rowspan="1" colspan="1">87.9 &#x000b1; 19.4<xref ref-type="table-fn" rid="tfn01t02">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1">+ 58.5</td></tr><tr><td rowspan="1" colspan="1">SDANN, ms</td><td align="center" rowspan="1" colspan="1">49.5 &#x000b1; 14.7</td><td align="center" rowspan="1" colspan="1">76.4 &#x000b1; 19.5<xref ref-type="table-fn" rid="tfn01t02">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1">+ 56.3</td></tr><tr><td rowspan="1" colspan="1">SDNN index, ms</td><td align="center" rowspan="1" colspan="1">24.7 &#x000b1; 8.8</td><td align="center" rowspan="1" colspan="1">38.3 &#x000b1; 13.1<xref ref-type="table-fn" rid="tfn01t02">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1">+ 55.3</td></tr><tr><td rowspan="1" colspan="1">RMSSD, ms</td><td align="center" rowspan="1" colspan="1">13.5 &#x000b1; 4.6</td><td align="center" rowspan="1" colspan="1">17.8 &#x000b1; 5.4<xref ref-type="table-fn" rid="tfn01t02">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1">+ 35.2</td></tr><tr><td rowspan="1" colspan="1">pNN50, %</td><td align="center" rowspan="1" colspan="1">2.4 &#x000b1; 1.6</td><td align="center" rowspan="1" colspan="1">3.2 &#x000b1; 2.2<xref ref-type="table-fn" rid="tfn01t02">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1">+ 43.3</td></tr></tbody></table><table-wrap-foot><fn id="tfn01t02"><label>&#x02020;</label><p>p &#x0003c; 0.0001 between before and after treatment</p></fn><fn><p>bpm: beats per min; HR: mean heart rate; HRV: heart rate variability; pNN50:
percentage of successive normal RR intervals exceeding 50 ms; RMSSD: the square
root of the mean of the squares of the differences between successive
normal-to-normal RR intervals; RR: mean RR interval; SDANN: the standard
deviation of 5-min mean RR intervals; SDNN: the standard deviation of all
normal-to-normal RR intervals; SDNN index: the mean of the standard deviation
of all normal to normal RR intervals for all 5-min segments.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t03" orientation="portrait" position="float"><label>Table 3</label><caption><p>Changes in time domain HRV indices of the study population when awake and while
asleep before and after ivabradine treatment</p></caption><table frame="hsides" rules="rows"><thead><tr><th rowspan="2" align="left" colspan="1">Variable</th><th rowspan="1" colspan="1">&#x000a0;</th><th rowspan="1" colspan="1">Awake</th><th rowspan="1" colspan="1">&#x000a0;</th><th rowspan="1" colspan="1">&#x000a0;</th><th rowspan="1" colspan="1">Asleep</th><th rowspan="1" colspan="1">&#x000a0;</th></tr><tr><th rowspan="1" colspan="1">Before treatment</th><th rowspan="1" colspan="1">After treatment</th><th rowspan="1" colspan="1">Change. %</th><th rowspan="1" colspan="1">Before treatment</th><th rowspan="1" colspan="1">After treatment</th><th rowspan="1" colspan="1">Change. %</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">HR, bpm</td><td align="center" rowspan="1" colspan="1">89.2 &#x000b1; 8.9</td><td align="center" rowspan="1" colspan="1">68.6 &#x000b1; 7.5<xref ref-type="table-fn" rid="tfn01t03">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1">- 31.2</td><td align="center" rowspan="1" colspan="1">79.7 &#x000b1; 7.7</td><td align="center" rowspan="1" colspan="1">61.4 &#x000b1; 5.5<xref ref-type="table-fn" rid="tfn02t03">&#x02021;</xref></td><td align="center" rowspan="1" colspan="1">- 22.5</td></tr><tr><td rowspan="1" colspan="1">RR interval, ms</td><td align="center" rowspan="1" colspan="1">656 &#x000b1; 86</td><td align="center" rowspan="1" colspan="1">848 &#x000b1; 66<xref ref-type="table-fn" rid="tfn01t03">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1">+ 29.9</td><td align="center" rowspan="1" colspan="1">748 &#x000b1; 82</td><td align="center" rowspan="1" colspan="1">956 &#x000b1; 105<xref ref-type="table-fn" rid="tfn02t03">&#x02021;</xref></td><td align="center" rowspan="1" colspan="1">+ 28.5</td></tr><tr><td rowspan="1" colspan="1">SDNN, ms</td><td align="center" rowspan="1" colspan="1">51.7 &#x000b1; 13.1</td><td align="center" rowspan="1" colspan="1">80.6 &#x000b1; 18.1<xref ref-type="table-fn" rid="tfn01t03">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1">+ 57.0</td><td align="center" rowspan="1" colspan="1">49.0 &#x000b1; 16.4</td><td align="center" rowspan="1" colspan="1">70.4 &#x000b1; 19.5<xref ref-type="table-fn" rid="tfn02t03">&#x02021;</xref></td><td align="center" rowspan="1" colspan="1">+ 46.3</td></tr><tr><td rowspan="1" colspan="1">SDANN, ms</td><td align="center" rowspan="1" colspan="1">46.3 &#x000b1; 13.9</td><td align="center" rowspan="1" colspan="1">71.0 &#x000b1; 19.8<xref ref-type="table-fn" rid="tfn01t03">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1">+ 54.0</td><td align="center" rowspan="1" colspan="1">44.2 &#x000b1; 14.9</td><td align="center" rowspan="1" colspan="1">66.3 &#x000b1; 21.7<xref ref-type="table-fn" rid="tfn02t03">&#x02021;</xref></td><td align="center" rowspan="1" colspan="1">+ 50.4</td></tr><tr><td rowspan="1" colspan="1">SDNN index, ms</td><td align="center" rowspan="1" colspan="1">22.8 &#x000b1; 8.0</td><td align="center" rowspan="1" colspan="1">34.9 &#x000b1; 12.2<xref ref-type="table-fn" rid="tfn01t03">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1">+ 53.4</td><td align="center" rowspan="1" colspan="1">22.2 &#x000b1; 10.3</td><td align="center" rowspan="1" colspan="1">32.2 &#x000b1; 13.3<xref ref-type="table-fn" rid="tfn02t03">&#x02021;</xref></td><td align="center" rowspan="1" colspan="1">+ 48.9</td></tr><tr><td rowspan="1" colspan="1">RMSSD, ms</td><td align="center" rowspan="1" colspan="1">11.0 &#x000b1; 3.2</td><td align="center" rowspan="1" colspan="1">14.1 &#x000b1; 3.8<xref ref-type="table-fn" rid="tfn01t03">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1">+ 29.2</td><td align="center" rowspan="1" colspan="1">17.0 &#x000b1; 4.9</td><td align="center" rowspan="1" colspan="1">24.3 &#x000b1; 6.0<xref ref-type="table-fn" rid="tfn02t03">&#x02021;</xref></td><td align="center" rowspan="1" colspan="1">+ 45.7</td></tr><tr><td rowspan="1" colspan="1">pNN50, %</td><td align="center" rowspan="1" colspan="1">2.1 &#x000b1; 1.6</td><td align="center" rowspan="1" colspan="1">2.7 &#x000b1; 2.3<xref ref-type="table-fn" rid="tfn01t03">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1">+ 32.9</td><td align="center" rowspan="1" colspan="1">3.5 &#x000b1; 1.9</td><td align="center" rowspan="1" colspan="1">5.1 &#x000b1; 2.5<xref ref-type="table-fn" rid="tfn02t03">&#x02021;</xref></td><td align="center" rowspan="1" colspan="1">+ 58.7</td></tr></tbody></table><table-wrap-foot><fn id="tfn01t03"><label>&#x02020;</label><p>p &#x0003c; 0.0001 between before and after treatment in awake period;</p></fn><fn id="tfn02t03"><label>&#x02021;</label><p>p &#x0003c; 0.0001 between before and after treatment in asleep period.</p></fn><fn><p>bpm: beats per min; HR: mean heart rate; HRV: heart rate variability; HRV
abbreviations as in <xref ref-type="table" rid="t02">Table 2</xref>.</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>Discussion</title><p>To our knowledge, this is the first study that assessed the effect of ivabradine on time
domain indices of HRV in patients with advanced heart failure. The main finding of our
study is that incorporating ivabradine in the treatment regimen of CHF patients who are
in sinus rhythm with a heart rate of &#x02265;70 bpm and are treated with guideline-based
background therapy (including maximally tolerated &#x003b2;-blockade) substantially
improves HRV. Our results showed that this improvement persisted both when the patient
was awake and while asleep.</p><p>Ivabradine is a novel heart rate-lowering agent, which modulates the spontaneous
diastolic depolarization in the sino-atrial node<sup><xref rid="r16" ref-type="bibr">16</xref></sup>. The spontaneous slow diastolic depolarization drives membrane
potential toward a threshold that triggers an action potential. The rate of spontaneous
diastolic depolarization is significantly influenced by If, a mixed sodium-potassium
current involving ion movement across the f-channels<sup><xref rid="r17" ref-type="bibr">17</xref></sup>. Ivabradine directly and selectively inhibits the If current,
reducing the diastolic depolarization time and heart rate. The specificity of ivabradine
for the If current ensures that ivabradine has no direct effects on myocardial
contractility (or relaxation), ventricular repolarization, or intracardiac conduction.
Thus, ivabradine has no negative inotropic or lusitropic effect<sup><xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r04" ref-type="bibr">4</xref></sup>.
Clinical trials have consistently demonstrated that lowering the heart rate by
administering ivabradine improves left ventricular (LV) functions, exercise capacity,
and quality of life of patients and reduces mortality in nonischemic and ischemic heart
failure patients independent of the dose of the &#x003b2;-blocker<sup><xref rid="r06" ref-type="bibr">6</xref>,<xref rid="r18" ref-type="bibr">18</xref>-<xref rid="r21" ref-type="bibr">21</xref></sup>. Therefore, the new Guidelines of the
European Society of Cardiology recommend the use of ivabradine in heart failure patients
with a sinus rhythm of at least 70 bpm<sup><xref rid="r01" ref-type="bibr">1</xref></sup>.</p><p>The HRV analysis is a well-established and noninvasive tool for monitoring the autonomic
control of the heart<sup><xref rid="r07" ref-type="bibr">7</xref></sup>. A heart rate
that is variable and responsive to demands is believed to bestow a survival advantage,
whereas reduced HRV may be associated with poor cardiovascular health and
outcomes<sup><xref rid="r07" ref-type="bibr">7</xref></sup>. Therefore,
alterations in cardiac autonomic control as measured by HRV may define subgroups with
higher risk for cardiovascular morbidity and mortality<sup><xref rid="r22" ref-type="bibr">22</xref></sup>. Analysis of HRV has recently been used to evaluate the
cardiac autonomic control both in normal subjects and in subjects with a wide variety of
cardiac and noncardiac disorders<sup><xref rid="r23" ref-type="bibr">23</xref>-<xref rid="r29" ref-type="bibr">29</xref></sup>. Of these cardiac disorders, nonischemic
DCM is associated with an increase in the sympathetic tone (with increased plasma
norepinephrine) and a withdrawal in vagal tone. In this group of patients, markedly
reduced HRV has been observed, which coincides with the severity of CHF as well as being
a significant prognostic factor for morbidity and mortality<sup><xref rid="r09" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref>,<xref rid="r12" ref-type="bibr">12</xref></sup>.</p><p>In our study, the mean RR interval, SDNN, SDANN, SDNNindex, pNN50, and RMSSD were found
to be low at baseline before ivabradine treatment. Our finding is consistent with the
results of earlier studies<sup><xref rid="r09" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref></sup>. Because impaired sympathovagal balance,
characterized by the sympathetic overactivity and parasympathetic withdrawal, is
considered to be a hallmark of the CHF-related morbidity and mortality, agents that
improve the sympathovagal balance may be of clinical significance. A variety of drugs,
including &#x003b2;-blockers, angiotensin converting enzyme inhibitors (ACEIs),
angiotensin receptor blockers (ARBs), and antialdosterone diuretics have been shown to
suppress sympathetic overactivity and improve HRV<sup><xref rid="r30" ref-type="bibr">30</xref>-<xref rid="r35" ref-type="bibr">35</xref></sup>. Aronson et
al<sup><xref rid="r30" ref-type="bibr">30</xref></sup> reported that
&#x003b2;-blockers have a beneficial modulating effect on HRV in CHF patients. Bullinga
et al<sup><xref rid="r31" ref-type="bibr">31</xref></sup> found that carvedilol therapy
in patients with CHF significantly increased HRV, which was also correlated with
improved hemodynamics. Jansson et al<sup><xref rid="r32" ref-type="bibr">32</xref></sup>
have shown the beneficial effects of metoprolol and captopril on HRV. A separate study
of the Tambara et al<sup><xref rid="r33" ref-type="bibr">33</xref></sup> found that
candesartan treatment improves the cardiac autonomic balance by attenuating the
sympathetic nervous activity and augmenting the parasympathetic activity in patients
with CHF<sup><xref rid="r33" ref-type="bibr">33</xref></sup>. Tommassi et al<sup><xref rid="r34" ref-type="bibr">34</xref></sup> reported that lisinopril treatment
enhanced HRV in patients with CHF. Further, aldosterone blockade with spironolactone was
shown to lower the heart rate and improve HRV in CHF patients<sup><xref rid="r35" ref-type="bibr">35</xref></sup>. However, the guideline-recommended target doses of
these drugs may not always be realized due to side effects such as dizziness, fatigue,
bradycardia, hypotension, and persistence of symptoms<sup><xref rid="r06" ref-type="bibr">6</xref>,<xref rid="r36" ref-type="bibr">36</xref>,<xref rid="r37" ref-type="bibr">37</xref></sup>. Therefore, combination therapy with ivabradine appears
to be valuable for patients who do not tolerate the target doses of beta-blockers,
ACEIs, ARBs, and diuretics. We found that 8 weeks of ivabradine treatment increased the
time domain indices of HRV in nonischemic DCM patients. This improvement was sustained
both when awake and while asleep. The possible mechanisms for this improvement may
include: 1) heart rate reduction with no negative effects on inotropism, which leads to
the lengthening of the diastolic filling time, permitting a more complete LV filling; 2)
beneficial effects on LV remodeling; 3) reducing the sympathetic influence and enhancing
the vagal tone as suggested by the decrease in SDNN and increase in pNN50 observed in
our study, leading to an improvement in the sympathovagal balance; and 4) suppression of
endothelial dysfunction<sup><xref rid="r04" ref-type="bibr">4</xref>,<xref rid="r38" ref-type="bibr">38</xref>-<xref rid="r40" ref-type="bibr">40</xref></sup>.</p><sec><title>Limitations</title><p>This study had several limitations. First, this was not a placebo-controlled,
randomized study. Second, the sample size of the study was relatively small and there
was no follow-up beyond 8 weeks. Therefore, the results obtained were not sufficient
to analyze the association between improved HRV and morbidity and mortality. While
HRV is of prognostic importance, its utility as a therapeutic target in HF patients
treated with ivabradine remains uncertain after this study. Third, because only
approximately half the number of patients were titrated to the recommended 7.5 mg
twice daily dose of ivabradine, the effect of the treatment may be underestimated.
Therefore, it is likely that the therapeutic potential and the clinical benefits of
ivabradine can be further increased by the use of the full dose as recommended.
Fourth, we have not measured the natriuretic peptide levels. Fifth, the heart rate
turbulence and frequency domain indices of HRV were not assessed in the present
study. Finally, CHF patients with NYHA class IV and COPD patients were not included
in the study.</p></sec></sec><sec sec-type="conclusions"><title>Conclusion</title><p>The present data indicate that appropriate ivabradine treatment may not only lower the
heart rate induced by sympathetic overactivity but also augment the parasympathetic
activity, thus improving cardiovascular autonomic regulation. This may reduce the risk
for morbidity and mortality in patients with long-term CHF. Further studies with larger
sample size are needed to assess the long-term beneficial effects of ivabradine
treatment on HRV in patients with CHF.</p></sec></body><back><fn-group><fn fn-type="con"><p><bold>Author contributions</bold></p><p>Conception and design of the research and Analysis and interpretation of the data:
Kurtoglu E, Balta S; Acquisition of data: Karakus Y, Yasar E, Cuglan B, Kaplan O,
Gozubuyuk G; Statistical analysis: Balta S, Karakus Y, Yasar E, Cuglan B; Writing of
the manuscript: Kurtoglu E; Critical revision of the manuscript for intellectual
content: Kaplan O, Gozubuyuk G.</p></fn><fn fn-type="conflict"><p><bold>Potential Conflict of Interest</bold></p><p>No potential conflict of interest relevant to this article was reported.</p></fn><fn fn-type="financial-disclosure"><p><bold>Sources of Funding</bold></p><p>There were no external funding sources for this study.</p></fn><fn fn-type="other"><p><bold>Study Association</bold></p><p>This study is not associated with any thesis or dissertation work.</p></fn></fn-group><ref-list><title>References</title><ref id="r01"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMurray</surname><given-names>JJ</given-names></name><name><surname>Adamopoulos</surname><given-names>S</given-names></name><name><surname>Anker</surname><given-names>SD</given-names></name><name><surname>Auricchio</surname><given-names>A</given-names></name><name><surname>B&#x000f6;hm</surname><given-names>M</given-names></name><name><surname>Dickstein</surname><given-names>K</given-names></name><etal>et al</etal><collab>ESC Committee for Practice Guidelines</collab></person-group><article-title>ESC guidelines for the diagnosis and treatment of acute and chronic
heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and
Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in
collaboration with the Heart Failure Association (HFA) of the ESC</article-title><source>Eur Heart J</source><year>2012</year><volume>33</volume><issue>14</issue><fpage>1787</fpage><lpage>1847</lpage><pub-id pub-id-type="pmid">22611136</pub-id></element-citation></ref><ref id="r02"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lloyd-Jones</surname><given-names>D</given-names></name><name><surname>Adams</surname><given-names>R</given-names></name><name><surname>Carnethon</surname><given-names>M</given-names></name><name><surname>De Simone</surname><given-names>G</given-names></name><name><surname>Ferguson</surname><given-names>TB</given-names></name><name><surname>Flegal</surname><given-names>K</given-names></name><etal>et al</etal></person-group><article-title>Heart disease and stroke statistics-2009 update: a report from the
American Heart Association Statistics Committee and Stroke Statistics
Subcommittee</article-title><source>Circulation</source><year>2009</year><volume>119</volume><issue>3</issue><fpage>480</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">19171871</pub-id></element-citation></ref><ref id="r03"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camm</surname><given-names>AJ</given-names></name><name><surname>Lau</surname><given-names>CP</given-names></name></person-group><article-title>Electrophysiological effects of a single intravenous administration of
ivabradine (S 16257) in adult patients with normal baseline
electrophysiology</article-title><source>Drugs</source><year>2003</year><volume>4</volume><issue>2</issue><fpage>83</fpage><lpage>89</lpage></element-citation></ref><ref id="r04"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manz</surname><given-names>M</given-names></name><name><surname>Reuter</surname><given-names>M</given-names></name><name><surname>Lauck</surname><given-names>G</given-names></name><name><surname>Omran</surname><given-names>H</given-names></name><name><surname>Jung</surname><given-names>W</given-names></name></person-group><article-title>A single intravenous dose of ivabradine, a novel I(f) inhibitor,
lowers heart rate but does not depress left ventricular function in patients with
left ventricular dysfunction</article-title><source>Cardiology</source><year>2003</year><volume>100</volume><issue>3</issue><fpage>149</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">14631136</pub-id></element-citation></ref><ref id="r05"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parakh</surname><given-names>N</given-names></name><name><surname>Chaturvedi</surname><given-names>V</given-names></name><name><surname>Kurian</surname><given-names>S</given-names></name><name><surname>Tyagi</surname><given-names>S</given-names></name></person-group><article-title>Effect of ivabradine vs atenolol on heart rate and effort tolerance in
patients with mild to moderate mitral stenosis and normal sinus
rhythm</article-title><source>J Card Fail</source><year>2012</year><volume>18</volume><issue>4</issue><fpage>282</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">22464768</pub-id></element-citation></ref><ref id="r06"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swedberg</surname><given-names>K</given-names></name><name><surname>Komajda</surname><given-names>M</given-names></name><name><surname>B&#x000f6;hm</surname><given-names>M</given-names></name><name><surname>Borer</surname><given-names>JS</given-names></name><name><surname>Ford</surname><given-names>I</given-names></name><name><surname>Dubost-Brama</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised
placebo-controlled study</article-title><source>Lancet</source><year>2010</year><volume>376</volume><issue>9744</issue><fpage>875</fpage><lpage>885</lpage><pub-id pub-id-type="pmid">20801500</pub-id></element-citation></ref><ref id="r07"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Task Force of the European Society of Cardiology</collab><collab>North American Society of Pacing and Electrophysiology</collab></person-group><article-title>Heart rate variability: standards of measurement, physiological
interpretation and clinical use</article-title><source>Circulation</source><year>1996</year><volume>93</volume><issue>5</issue><fpage>1043</fpage><lpage>1065</lpage><pub-id pub-id-type="pmid">8598068</pub-id></element-citation></ref><ref id="r08"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitzalis</surname><given-names>MV</given-names></name><name><surname>Mastropasqua</surname><given-names>F</given-names></name><name><surname>Massari</surname><given-names>F</given-names></name><name><surname>Forleo</surname><given-names>C</given-names></name><name><surname>Di Maggio</surname><given-names>M</given-names></name><name><surname>Passantino</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Short- and long-term reproducibility of time and frequency domain
heart rate variability measurements in normal subjects</article-title><source>Cardiovasc Res</source><year>1996</year><volume>32</volume><issue>2</issue><fpage>226</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">8796108</pub-id></element-citation></ref><ref id="r09"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karcz</surname><given-names>M</given-names></name><name><surname>Chojnowska</surname><given-names>L</given-names></name><name><surname>Zareba</surname><given-names>W</given-names></name><name><surname>Ruzyllo</surname><given-names>W</given-names></name></person-group><article-title>Prognostic significance of heart rate variability in dilated
cardiomyopathy</article-title><source>Int J Cardiol</source><year>2003</year><volume>87</volume><issue>1</issue><fpage>75</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">12468057</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fauchier</surname><given-names>L</given-names></name><name><surname>Babuty</surname><given-names>D</given-names></name><name><surname>Cosnay</surname><given-names>P</given-names></name><name><surname>Autret</surname><given-names>ML</given-names></name><name><surname>Fauchier</surname><given-names>JP</given-names></name></person-group><article-title>Heart rate variability in idiopathic dilated cardiomyopathy:
characteristics and prognostic value</article-title><source>J Am Coll Cardiol</source><year>1997</year><volume>30</volume><issue>4</issue><fpage>1009</fpage><lpage>1014</lpage><pub-id pub-id-type="pmid">9316532</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Binkley</surname><given-names>PF</given-names></name></person-group><article-title>Heart rate variability: two eras of investigation</article-title><source>J Card Fail</source><year>1996</year><volume>2</volume><issue>3</issue><fpage>193</fpage><lpage>196</lpage><pub-id pub-id-type="pmid">8891857</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bilchick</surname><given-names>KC</given-names></name><name><surname>Fetics</surname><given-names>B</given-names></name><name><surname>Djoukeng</surname><given-names>R</given-names></name><name><surname>Fisher</surname><given-names>SG</given-names></name><name><surname>Fletcher</surname><given-names>RD</given-names></name><name><surname>Singh</surname><given-names>SN</given-names></name><etal>et al</etal></person-group><article-title>Prognostic value of heart rate variability in chronic congestive heart
failure (Veterans Affairs' Survival Trial of Antiarrhythmic Therapy in Congestive
Heart Failure)</article-title><source>Am J Cardiol</source><year>2002</year><volume>90</volume><issue>1</issue><fpage>24</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">12088774</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manolis</surname><given-names>AJ</given-names></name><name><surname>Poulimenos</surname><given-names>LE</given-names></name><name><surname>Kallistratos</surname><given-names>MS</given-names></name><name><surname>Gavras</surname><given-names>I</given-names></name><name><surname>Gavras</surname><given-names>H</given-names></name></person-group><article-title>Sympathetic overactivity in hypertension and cardiovascular
disease</article-title><source>Curr Vasc Pharmacol</source><year>2014</year><volume>12</volume><issue>1</issue><fpage>4</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">23905597</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tardif</surname><given-names>JC</given-names></name><name><surname>Ponikowski</surname><given-names>P</given-names></name><name><surname>Kahan</surname><given-names>T</given-names></name><collab>ASSOCIATE investigators</collab></person-group><article-title>Effects of ivabradine in patients with stable angina receiving
beta-blockers according to baseline heart rate: an analysis of the ASSOCIATE
study</article-title><source>Int J Cardiol</source><year>2013</year><volume>168</volume><issue>2</issue><fpage>789</fpage><lpage>794</lpage><pub-id pub-id-type="pmid">23138014</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Picard</surname><given-names>MH</given-names></name><name><surname>Adams</surname><given-names>D</given-names></name><name><surname>Bierig</surname><given-names>SM</given-names></name><name><surname>Dent</surname><given-names>JM</given-names></name><name><surname>Douglas</surname><given-names>PS</given-names></name><name><surname>Gillam</surname><given-names>LD</given-names></name><etal>et al</etal></person-group><article-title>American Society of Echocardiography recommendations for quality
echocardiography laboratory operations</article-title><source>J Am Soc Echocardiogr</source><year>2011</year><volume>24</volume><issue>1</issue><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">21172594</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Francesco</surname><given-names>D</given-names></name><name><surname>Camm</surname><given-names>AJ</given-names></name></person-group><article-title>Heart rate lowering by specific and selective I(f) current inhibition
with ivabradine: a new therapeutic perspective in cardiovascular
disease</article-title><source>Drugs</source><year>2004</year><volume>64</volume><issue>16</issue><fpage>1757</fpage><lpage>1765</lpage><pub-id pub-id-type="pmid">15301560</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bucchi</surname><given-names>A</given-names></name><name><surname>Tognati</surname><given-names>A</given-names></name><name><surname>Milanesi</surname><given-names>R</given-names></name><name><surname>Baruscotti</surname><given-names>M</given-names></name><name><surname>DiFrancesco</surname><given-names>D</given-names></name></person-group><article-title>Properties of ivabradine induced block of HCN1 and HCN4 pacemaker
channels</article-title><source>J Physiol</source><year>2006</year><volume>572</volume><issue-part>Pt 2</issue-part><fpage>335</fpage><lpage>346</lpage><pub-id pub-id-type="pmid">16484306</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>K</given-names></name><name><surname>Ford</surname><given-names>I</given-names></name><name><surname>Steg</surname><given-names>PG</given-names></name><name><surname>Tendera</surname><given-names>M</given-names></name><name><surname>Robertson</surname><given-names>M</given-names></name><name><surname>Ferrari</surname><given-names>R</given-names></name><collab>BEAUTIFUL Investigators</collab></person-group><article-title>Relationship between ivabradine treatment and cardiovascular outcomes
in patients with stable coronary artery disease and left ventricular systolic
dysfunction with limiting angina: a subgroup analysis of the randomized,
controlled BEAUTIFUL trial</article-title><source>Eur Heart J</source><year>2009</year><volume>30</volume><issue>19</issue><fpage>2337</fpage><lpage>2345</lpage><pub-id pub-id-type="pmid">19720635</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarullo</surname><given-names>FM</given-names></name><name><surname>Fazio</surname><given-names>G</given-names></name><name><surname>Puccio</surname><given-names>D</given-names></name><name><surname>Fasullo</surname><given-names>S</given-names></name><name><surname>Paterna</surname><given-names>S</given-names></name><name><surname>Novo</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Impact of "off-label" use of ivabradine on exercise capacity, gas
exchange, functional class, quality of life, and neurohormonal modulation in
patients with ischemic chronic heart failure</article-title><source>J Cardiovasc Pharmacol Ther</source><year>2010</year><volume>15</volume><issue>4</issue><fpage>349</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">20940450</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volterrani</surname><given-names>M</given-names></name><name><surname>Cice</surname><given-names>G</given-names></name><name><surname>Caminiti</surname><given-names>G</given-names></name><name><surname>Vitale</surname><given-names>C</given-names></name><name><surname>D'Isa</surname><given-names>S</given-names></name><name><surname>Perrone Filardi</surname><given-names>P</given-names></name><etal>et al</etal></person-group><article-title>Effect of Carvedilol, Ivabradine or their combination on exercise
capacity in patients with Heart Failure (the CARVIVA HF trial)</article-title><source>Int J Cardiol</source><year>2011</year><volume>151</volume><issue>2</issue><fpage>218</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">21764469</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fasullo</surname><given-names>S</given-names></name><name><surname>Cannizzaro</surname><given-names>S</given-names></name><name><surname>Maringhini</surname><given-names>G</given-names></name><name><surname>Ganci</surname><given-names>F</given-names></name><name><surname>Giambanco</surname><given-names>F</given-names></name><name><surname>Vitale</surname><given-names>G</given-names></name><etal>et al</etal></person-group><article-title>Comparison of ivabradine versus metoprolol in early phases of
reperfused anterior myocardial infarction with impaired left ventricular function:
preliminary findings</article-title><source>J Card Fail</source><year>2009</year><volume>15</volume><issue>10</issue><fpage>856</fpage><lpage>863</lpage><pub-id pub-id-type="pmid">19944362</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuji</surname><given-names>H</given-names></name><name><surname>Venditti</surname><given-names>FJ</given-names><suffix>Jr</suffix></name><name><surname>Manders</surname><given-names>ES</given-names></name><name><surname>Evans</surname><given-names>JC</given-names></name><name><surname>Larson</surname><given-names>MG</given-names></name><name><surname>Feldman</surname><given-names>CL</given-names></name><etal>et al</etal></person-group><article-title>Reduced heart rate variability and mortality risk in an elderly
cohort. The Framingham Heart Study</article-title><source>Circulation</source><year>1994</year><volume>90</volume><issue>2</issue><fpage>878</fpage><lpage>883</lpage><pub-id pub-id-type="pmid">8044959</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dogru</surname><given-names>MT</given-names></name><name><surname>Simsek</surname><given-names>V</given-names></name><name><surname>Sahin</surname><given-names>O</given-names></name><name><surname>Ozer</surname><given-names>N</given-names></name></person-group><article-title>Differences in autonomic activity in individuals with optimal, normal,
and high-normal blood pressure levels</article-title><source>Turk Kardiyol Dern Ars</source><year>2010</year><volume>38</volume><issue>3</issue><fpage>182</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">20675995</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turker</surname><given-names>Y</given-names></name><name><surname>Aslantas</surname><given-names>Y</given-names></name><name><surname>Aydin</surname><given-names>Y</given-names></name><name><surname>Demirin</surname><given-names>H</given-names></name><name><surname>Kutlucan</surname><given-names>A</given-names></name><name><surname>Tibilli</surname><given-names>H</given-names></name><etal>et al</etal></person-group><article-title>Heart rate variability and heart rate recovery in patients with type 1
diabetes mellitus</article-title><source>Acta Cardiol</source><year>2013</year><volume>68</volume><issue>2</issue><fpage>145</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">23705556</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>SA</given-names></name><name><surname>Kambur</surname><given-names>T</given-names></name><name><surname>Chan</surname><given-names>C</given-names></name><name><surname>Herrington</surname><given-names>DM</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Shah</surname><given-names>SJ</given-names></name></person-group><article-title>Relation of short-term heart rate variability to incident heart
failure (from the Multi-Ethnic Study of Atherosclerosis)</article-title><source>Am J Cardiol</source><year>2013</year><volume>112</volume><issue>4</issue><fpage>533</fpage><lpage>540</lpage><pub-id pub-id-type="pmid">23683953</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coviello</surname><given-names>I</given-names></name><name><surname>Pinnacchio</surname><given-names>G</given-names></name><name><surname>Laurito</surname><given-names>M</given-names></name><name><surname>Stazi</surname><given-names>A</given-names></name><name><surname>Battipaglia</surname><given-names>I</given-names></name><name><surname>Barone</surname><given-names>L</given-names></name><etal>et al</etal></person-group><article-title>Prognostic role of heart rate variability in patients with ST-segment
elevation acute myocardial infarction treated by primary
angioplasty</article-title><source>Cardiology</source><year>2013</year><volume>124</volume><issue>1</issue><fpage>63</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">23328532</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munjal</surname><given-names>S</given-names></name><name><surname>Koval</surname><given-names>T</given-names></name><name><surname>Muhammad</surname><given-names>R</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Demmel</surname><given-names>V</given-names></name><name><surname>Roethig</surname><given-names>HJ</given-names></name><etal>et al</etal></person-group><article-title>Heart rate variability increases with reductions in cigarette smoke
exposure after 3 days</article-title><source>J Cardiovasc Pharmacol Ther</source><year>2009</year><volume>14</volume><issue>3</issue><fpage>192</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">19592602</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antelmi</surname><given-names>I</given-names></name><name><surname>de Paula</surname><given-names>RS</given-names></name><name><surname>Shinzato</surname><given-names>AR</given-names></name><name><surname>Peres</surname><given-names>CA</given-names></name><name><surname>Mansur</surname><given-names>AJ</given-names></name><name><surname>Grupi</surname><given-names>CJ</given-names></name></person-group><article-title>Influence of age, gender, body mass index, and functional capacity on
heart rate variability in a cohort of subjects without heart
disease</article-title><source>Am J Cardiol</source><year>2004</year><volume>93</volume><issue>3</issue><fpage>381</fpage><lpage>385</lpage><pub-id pub-id-type="pmid">14759400</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurtoglu</surname><given-names>E</given-names></name><name><surname>Akturk</surname><given-names>E</given-names></name><name><surname>Korkmaz</surname><given-names>H</given-names></name><name><surname>Atas</surname><given-names>H</given-names></name><name><surname>Cuglan</surname><given-names>B</given-names></name><name><surname>Pekdemir</surname><given-names>H</given-names></name></person-group><article-title>Impaired heart rate variability in patients with mitral annular
calcification: an observational study</article-title><source>Anadolu Kardiyol Derg</source><year>2013</year><volume>13</volume><issue>7</issue><fpage>668</fpage><lpage>674</lpage><pub-id pub-id-type="pmid">23912789</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aronson</surname><given-names>D</given-names></name><name><surname>Burger</surname><given-names>AJ</given-names></name></person-group><article-title>Effect of beta-blockade on heart rate variability in decompensated
heart failure</article-title><source>Int J Cardiol</source><year>2001</year><volume>79</volume><issue>1</issue><fpage>31</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">11399339</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bullinga</surname><given-names>JR</given-names></name><name><surname>Alharethi</surname><given-names>R</given-names></name><name><surname>Schram</surname><given-names>MS</given-names></name><name><surname>Bristow</surname><given-names>MR</given-names></name><name><surname>Gilbert</surname><given-names>EM</given-names></name></person-group><article-title>Changes in heart rate variability are correlated to hemodynamic
improvement with chronic CARVEDILOL therapy in heart failure</article-title><source>J Card Fail</source><year>2005</year><volume>11</volume><issue>9</issue><fpage>693</fpage><lpage>699</lpage><pub-id pub-id-type="pmid">16360965</pub-id></element-citation></ref><ref id="r32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jansson</surname><given-names>K</given-names></name><name><surname>Hagerman</surname><given-names>I</given-names></name><name><surname>Ostlund</surname><given-names>R</given-names></name><name><surname>Karlberg</surname><given-names>KE</given-names></name><name><surname>Nylander</surname><given-names>E</given-names></name><name><surname>Nyquist</surname><given-names>O</given-names></name><etal>et al</etal></person-group><article-title>The effects of metoprolol and captopril on heart rate variability in
patients with idiopathic dilated cardiomyopathy</article-title><source>Clin Cardiol</source><year>1999</year><volume>22</volume><issue>6</issue><fpage>397</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">10376178</pub-id></element-citation></ref><ref id="r33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tambara</surname><given-names>K</given-names></name><name><surname>Fujita</surname><given-names>M</given-names></name><name><surname>Sumita</surname><given-names>Y</given-names></name><name><surname>Miyamoto</surname><given-names>S</given-names></name><name><surname>Sekiguchi</surname><given-names>H</given-names></name><name><surname>Eiho</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Beneficial effect of candesartan treatment on cardiac autonomic
nervous activity in patients with chronic heart failure: simultaneous recording of
ambulatory electrocardiogram and posture</article-title><source>Clin Cardiol</source><year>2004</year><volume>27</volume><issue>5</issue><fpage>300</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">15188948</pub-id></element-citation></ref><ref id="r34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Tommasi</surname><given-names>E</given-names></name><name><surname>Iacoviello</surname><given-names>M</given-names></name><name><surname>Romito</surname><given-names>R</given-names></name><name><surname>Ceconi</surname><given-names>C</given-names></name><name><surname>Guida</surname><given-names>P</given-names></name><name><surname>Massari</surname><given-names>F</given-names></name><etal>et al</etal></person-group><article-title>Comparison of the effect of valsartan and lisinopril on autonomic
nervous system activity in chronic heart failure</article-title><source>Am Heart J</source><year>2003</year><volume>146</volume><issue>5</issue><elocation-id/></element-citation></ref><ref id="r35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yee</surname><given-names>KM</given-names></name><name><surname>Pringle</surname><given-names>SD</given-names></name><name><surname>Struthers</surname><given-names>AD</given-names></name></person-group><article-title>Circadian variation in the effects of aldosterone blockade on heart
rate variability and QT dispersion in congestive heart failure</article-title><source>J Am Coll Cardiol</source><year>2001</year><volume>37</volume><issue>7</issue><fpage>1800</fpage><lpage>1807</lpage><pub-id pub-id-type="pmid">11401114</pub-id></element-citation></ref><ref id="r36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gislason</surname><given-names>GH</given-names></name><name><surname>Rasmussen</surname><given-names>V</given-names></name><name><surname>Abildstrom</surname><given-names>SZ</given-names></name><name><surname>Gadsboll</surname><given-names>N</given-names></name><name><surname>Buch</surname><given-names>P</given-names></name><name><surname>Friberg</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Long-term compliance with beta-blockers, angiotensin-converting enzyme
inhibitors, and statins after acute myocardial infarction</article-title><source>Eur Heart J</source><year>2006</year><volume>27</volume><issue>10</issue><fpage>1153</fpage><lpage>1158</lpage><pub-id pub-id-type="pmid">16399775</pub-id></element-citation></ref><ref id="r37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Follath</surname><given-names>F</given-names></name></person-group><article-title>Challenging the dogma of high target doses in the treatment of heart
failure: is more always better?</article-title><source>Arch Cardiovasc Dis</source><year>2009</year><volume>102</volume><issue>11</issue><fpage>785</fpage><lpage>789</lpage><pub-id pub-id-type="pmid">19944395</pub-id></element-citation></ref><ref id="r38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busseuil</surname><given-names>D</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Mecteau</surname><given-names>M</given-names></name><name><surname>Brand</surname><given-names>G</given-names></name><name><surname>Gillis</surname><given-names>MA</given-names></name><name><surname>Thorin</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>Heart rate reduction by ivabradine reduces diastolic dysfunction and
cardiac fibrosis</article-title><source>Cardiology</source><year>2010</year><volume>117</volume><issue>3</issue><fpage>234</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">21212673</pub-id></element-citation></ref><ref id="r39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tardif</surname><given-names>JC</given-names></name><name><surname>O'Meara</surname><given-names>E</given-names></name><name><surname>Komajda</surname><given-names>M</given-names></name><name><surname>B&#x000f6;hm</surname><given-names>M</given-names></name><name><surname>Borer</surname><given-names>JS</given-names></name><name><surname>Ford</surname><given-names>I</given-names></name><etal>et al</etal><collab>SHIFT Investigators</collab></person-group><article-title>Effects of selective heart rate reduction with ivabradine on left
ventricular remodelling and function: results from the SHIFT echocardiography
substudy</article-title><source>Eur Heart J</source><year>2011</year><volume>32</volume><issue>20</issue><fpage>2507</fpage><lpage>2515</lpage><pub-id pub-id-type="pmid">21875858</pub-id></element-citation></ref><ref id="r40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drouin</surname><given-names>A</given-names></name><name><surname>Gendron</surname><given-names>ME</given-names></name><name><surname>Thorin</surname><given-names>E</given-names></name><name><surname>Gillis</surname><given-names>MA</given-names></name><name><surname>Mahlberg-Gaudin</surname><given-names>F</given-names></name><name><surname>Tardif</surname><given-names>JC</given-names></name></person-group><article-title>Chronic heart rate reduction by ivabradine prevents endothelial
dysfunction in dyslipidaemic mice</article-title><source>Br J Pharmacol</source><year>2008</year><volume>154</volume><issue>4</issue><fpage>749</fpage><lpage>757</lpage><pub-id pub-id-type="pmid">18414390</pub-id></element-citation></ref></ref-list></back></article>